Business
Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040
Once issued, this new U.S. patent covers the use of CardiolRx™ and CRD-38 for a broad rang...
About this update from Cardiol Therapeutics Inc. Class A
[{"type":"text","content":"Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040Once issued, this new U.S. patent covers the use of CardiolRx™ and CRD-38 for a broad range of cardiac disorders, including atherosclerosis and heart failure, significantly expanding intellectual property protection in the world's largest pharmaceutical market.This allowance fortifies Cardiol's global intellectual property portfolio, adding to granted and pending patent applications in Europe, Japan, Canada, Australia, and China.Toronto, Ontario--(Newsfile Corp. - November 13, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (\"Cardiol\" or the \"Company\"), a clinical-stage life sciences company developing anti-inflammatory and anti-fibrotic therapies for heart disease, announces that it has received a Notice of Allowance for the Company's U.S. patent application entitled \"Cannabidiol Compositions for Use in Treating Heart Conditions\" from the United States Patent and Trademark Office. Once issued, the new patent will establish broad intellectual property (I.P.) protection for the use of CardiolRx™ and CRD-38 in the treatment or prevention of an extensive range of cardiac conditions, including heart failure, myocarditis, acute pericarditis, inflammatory cardiomyopathy, cardiac toxicity from anti-cancer therapies, and atherosclerosis, to October 2040.\"This important milestone extends our I.P. protection to the world's largest pharmaceutical market,\" said David Elsley, President and Chief Executive Officer of Cardiol Therapeutics. \"Together with our U.S. Orphan Drug Designation for pericarditis, this new patent allowance fortifies Cardiol's market position and I.P. portfolio, providing broad protection across a diverse range of heart diseases characterized by inflammation and fibrosis. This expanded exclusivity coverage also reinforces the long-term value of our pipeline as we advance late-stage clinical programs in recurrent pericarditis and acute myocarditis-inflammatory heart diseases with significant unmet medical needs-and as we prepare to initiate first-in-human clinical evaluation of CRD-38, our novel subcutaneously administered therapy for inflammatory heart disease, including heart failure. By securing this protection through late 2040, we are solidifying a strong foundation to support our glo...